ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 834

Interleukin-18 (IL-18) As a Biomarker for Diagnosis and Evaluation of Disease Activity in Patients with Adult Onset Still’s Disease and Systemic Onset Juvenile Idiopathic Arthritis

Holger Kudela1, Susanne Drynda2, Anke Lux3, Gerd Horneff4 and Joern Kekow2, 1Univ of Magdeburg, Clinic for Rheumatology, Vogelsang-Gommern, Germany, 2Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, 3Univ of Magdeburg, Institute for Biometry and Medical Informatics, Magdeburg, Germany, 4Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: IL-1/IL-18, Systemic JIA and adult-onset Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Establishing the diagnosis of adult onset Still’s disease (AOSD) as well as of systemic onset juvenile idiopathic arthritis (sJIA) is very challenging. Mostly it is still a diagnosis of exclusion. Along with IL-1β, IL-6 and TNFα, IL-18 is one of the cytokines which seem to play a pivotal role in the pathogenesis of both diseases. It has been described as a potential biomarker to support the diagnosis of AOSD and sJIA. Regarding the importance of IL-18 as a marker for disease activity published data are so far conflicting. The aim of the study was to clarify the role of IL-18 as a diagnostic marker and its importance as a measure for disease activity in AOSD and sJIA.

Methods: Thirty adult patients diagnosed with AOSD and twenty children diagnosed with sJIA were included in the study.  Twenty adults and three children were analyzed repeatedly.  At each visit patients underwent clinical evaluation and laboratory analysis. IL-18 serum levels were determined using an IL-18 ELISA (MBL, Japan) according to the manufacturer’s instructions. As comparison groups served 65 adults and 23 children with other rheumatic diseases. To evaluate the disease activity Rau’s criteria and CRP values were used.  Active disease was defined as a Rau’s score ≥2 and/or CRP≥ 2 ULN. 

Results: In 83 samples from 30 AOSD patients IL-18 levels were determined. At the time of blood sample collection clinical parameters were obtained as well. In active disease (n=27) patients showed a mean activity score of 3.9±1.4 and a mean CRP value of 106.5±86.1 mg/l. Patients in remission (n=43) showed a mean activity score of 0.14±0.35, and mean CRP value of 5.6±1.5 mg/l. IL-18 levels were significantly increased in patients with active AOSD compared to patients in remission and to the comparison group with a median of 16327 pg/ml, 470 pg/ml, and 368 pg/ml, respectively (p<0,001). In active disease (n=16) the sJIA cohort showed a mean activity score of 3.4±1.0 and mean CRP value of 133.9±81.8 mg/l.  Analogous to AOSD in active sJIA the median IL-18 serum level with 21512 pg/ml was significantly higher than in the comparison group (n=25) with a median IL-18 serum level of 2580 pg/ml (p<0.001) and a mean CRP value of 67.6±77.7 mg/l .

For evaluation of IL-18 serum levels as marker for AOSD or sJIA a receiver operating characteristic curve analysis was used.  At a cutoff point of 5000 pg/ml IL-18 specificity for AOSD was 96.9 %, and sensitivity 63.3 % (AUC=0.870, p<0.001). For diagnosis of sJIA in children a cutoff value of 10000 pg/ml was chosen with a specificity of 100 % and a sensitivity of 60 % (AUC=0.774, p = 0.003).

In 11 AOSD patients with active disease at the first visit (Rau’s score 4.2±1.5) the reduction of disease activity (Rau’s score 0.4±0.7) went along with a significant reduction in IL-18 serum levels from medians of 12500 pg/ml to 402 pg/ml (Wilcoxon sign rank test p<0,001).  

Conclusion: We could confirm earlier publications that highly elevated IL-18 serum levels are common in active AOSD and sJIA, with up to 1000fold higher concentrations compared to other rheumatic diseases. A clear association of IL-18 serum levels with disease activity in AOSD was found. The results give further evidence for the use of IL-18 as diagnostic biomarker in AOSD and sJIA.


Disclosure:

H. Kudela,
None;

S. Drynda,
None;

A. Lux,
None;

G. Horneff,
None;

J. Kekow,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-18-il-18-as-a-biomarker-for-diagnosis-and-evaluation-of-disease-activity-in-patients-with-adult-onset-stills-disease-and-systemic-onset-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology